EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions

Fernanda Fortunato, Alessandra Ferlini

Journal of Neuromuscular Diseases · 07.11.2023 · 10 (6) · 987-1002

DOI: 10.3233/jnd-221666 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 29.07.2023. Verfasst von Fernanda Fortunato und 1 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, MicroRNAs, Biomedical Research. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy is a severe, X-linked disease characterized by decreased muscle mass and function in children. Genetic and biochemical research over the years has led to the characterization of the cause and the pathophysiology of the disease. Moreover, the elucidation of genetic mechanisms underlining Duchenne muscular dystrophy has allowed for the design of innovative personalized therapies. The identification of specific, accurate, and sensitive biomarkers is becoming crucial for evaluating muscle disease progression and response to therapies, disease monitoring, and the acceleration of drug development and related regulatory processes. This review illustrated the up-to-date progress in the development of candidate biomarkers in DMD at the level of proteins, metabolites, micro-RNAs (miRNAs) and genetic modifiers also highlighting the complexity of translating research results to clinical practice. We highlighted the challenges encountered in translating biomarkers into the clinical context and the existing bottlenecks hampering the adoption of biomarkers as surrogate endpoints. These challenges could be overcome by national and international collaborative efforts, multicenter data sharing, definition of public biobanks and patients’ registries, and creation of large cohorts of patients. Novel statistical tools/ models suitable to analyze small patient numbers are also required. Finally, collaborations with pharmaceutical companies would greatly benefit biomarker discovery and their translation in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneMicroRNAsBiomedical ResearchChildHumansMuscle, SkeletalBiomarkersMulticenter Studies as Topic

Stichwörter der Autor:innen

Duchenne muscular dystrophybiomarkersmiRNAsproteinssingle nucleotide polymorphisms

Substanzen

MicroRNAsBiomarkers

Autor:innen und Institutionen

  • Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Zitieren

APA

Fortunato, F., & Ferlini, A. (2023). Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions. Journal of Neuromuscular Diseases, 10(6), 987-1002. https://doi.org/10.3233/jnd-221666

Vancouver

Fortunato F, Ferlini A. Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions. Journal of Neuromuscular Diseases. 2023;10(6):987-1002. doi:10.3233/jnd-221666

BibTeX
@article{Fortunato2023,
  author = {Fortunato, Fernanda and Ferlini, Alessandra},
  title = {Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions},
  journal = {Journal of Neuromuscular Diseases},
  year = {2023},
  volume = {10},
  number = {6},
  pages = {987--1002},
  doi = {10.3233/jnd-221666}
}
Kostenlos starten →